Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271804 · ClinicalTrials.gov registry record · Phase 1
Study of Velcade and Thalidomide in Patients With Myelodysplasia
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00271804: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00271804 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00271804, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what the maximal tolerated dose of Velcade can be given with thalidomide in patients with myelodysplasia.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00271804
The ClinicalTrials.gov registry entry for NCT00271804 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00271804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00271804 about?
NCT00271804 is a clinical study titled "Study of Velcade and Thalidomide in Patients With Myelodysplasia". The purpose of this study is to find out what the maximal tolerated dose of Velcade can be given with thalidomide in patients with myelodysplasia.
What is the current status of trial NCT00271804?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2005-06. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00271804?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00271804?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.